ストックスクリーナーアプリを入手
7.59
4.29%
-0.34
前日終値:
$7.93
開ける：
$7.9
24時間の取引高:
2.05M
Relative Volume:
1.90
時価総額：
$417.07M
収益：
$3.64M
当期純損益:
$-87.37M
株価収益率:
-1.8467
EPS:
-4.11
ネットキャッシュフロー:
$-86.46M
1週間 パフォーマンス:
+5.86%
1か月 パフォーマンス:
+53.02%
6か月 パフォーマンス:
+90.23%
1年 パフォーマンス:
-37.43%
1日の値動き範囲:
$7.49
$8.015
1週間の範囲:
$6.53
$8.35
52週間の値動き範囲:
$2.10
$12.45
Verastem Inc Stock (VSTM) Company Profile
VSTM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
7.59 | 369.18M | 3.64M | -87.37M | -86.46M | -4.11 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Jefferies | Buy |
| 2025-03-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-31 | 繰り返されました | BTIG Research | Buy |
| 2024-09-30 | 開始されました | Guggenheim | Buy |
| 2023-11-21 | 再開されました | BTIG Research | Buy |
| 2023-09-27 | 開始されました | B. Riley Securities | Buy |
| 2023-06-15 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-07 | 再開されました | Alliance Global Partners | Buy |
| 2022-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-03-09 | 開始されました | Truist | Buy |
| 2021-07-01 | 開始されました | Alliance Global Partners | Buy |
| 2021-05-24 | アップグレード | BTIG Research | Neutral → Buy |
| 2019-06-20 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-05-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 開始されました | BTIG Research | Buy |
| 2018-05-02 | 開始されました | Seaport Global Securities | Buy |
| 2018-03-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-13 | 開始されました | Oppenheimer | Outperform |
| 2017-03-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-09-29 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2015-09-29 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | ダウングレード | Mizuho | Buy → Neutral |
| 2015-09-28 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 開始されました | Raymond James | Strong Buy |
| 2015-05-12 | 繰り返されました | UBS | Buy |
| 2015-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2015-01-23 | 繰り返されました | ROTH Capital | Buy |
| 2014-07-08 | 再開されました | Oppenheimer | Perform |
| 2014-02-11 | 開始されました | Mizuho | Buy |
すべてを表示
Verastem Inc (VSTM) 最新ニュース
Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Sto - GuruFocus
Verastem: Q1 Earnings Snapshot - Greenwich Time
Verastem (VSTM) Advances Pipeline with Key Developments | VSTM S - GuruFocus
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem Oncology Reports First Quarter 2025 Financial Results a - GuruFocus
Verastem, Inc. SEC 10-Q Report - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolent Health (EVH), Verastem (VSTM) and Sight Sciences (SGHT) - The Globe and Mail
Today's Research Reports on Stocks to Watch: Alder BioPharmaceuticals Inc. and Verastem Inc. - ACCESS Newswire
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased - MSN
Verastem (VSTM) Sees Price Target Increase and FDA Approval Boos - GuruFocus
Verastem (VSTM) Sees Increased Price Target Following FDA Approval | VSTM Stock News - GuruFocus
High-graded low-grade ovarian duo wins for Verastem at FDA - BioWorld MedTech
B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating - marketscreener.com
Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating - marketscreener.com
Verastem (VSTM) Stock Update: Analyst Raises Price Target to $14 | VSTM Stock News - GuruFocus
RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Verastem (VSTM) Price Target Increased by RBC Capital Analyst | VSTM Stock News - GuruFocus
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer - BioSpace
Verastem stock price target raised to $19 by Jefferies - Investing.com Canada
Verastem Gains FDA Approval for New Cancer Treatment - TipRanks
Health Care Stocks See Mixed Results In Market Movements - Finimize
Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer - insights.citeline.com
Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer - MedCity News
FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC - Pharmacy Times
US FDA approves Verastem's ovarian cancer therapy - Reuters
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian CancerVerastem (NASDAQ:VSTM) - Benzinga
US FDA approves Verastem’s cancer therapy - WHTC
Verastem (VSTM) Gains as Analyst Increases Price Target Following FDA Approval | VSTM Stock News - GuruFocus
Verastem Oncology Cancer Drug Combination Gets FDA Approval - marketscreener.com
FDA grants Verastem first approval for rare ovarian cancer treatment - Endpoints News
Verastem Says AVMAPKI FAKZYNJA Co-Pack Expected To Be Available For Adult Patients In U.S. In One Week - marketscreener.com
FDA Greenlights Verastem's (VSTM) New Cancer Treatment - GuruFocus
Verastem's Avmapki Fakzynja receives FDA accelerated approval for ovarian cancer - Seeking Alpha
U.S. FDA approves Verastem's cancer therapy - marketscreener.com
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo - GuruFocus
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo | VSTM Stock News - GuruFocus
Trading (VSTM) With Integrated Risk Controls - news.stocktradersdaily.com
Invesco Ltd. Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
B. Riley Issues Pessimistic Outlook for Verastem Earnings - Defense World
Verastem (VSTM) Schedules Conference Call with Key Executives | - GuruFocus
Verastem Oncology to Present at Upcoming Investor Conferences | - GuruFocus
Ovarian Cancer Market: Epidemiology, Therapies, Companies, - openPR.com
Verastem Oncology to Present at Upcoming Investor Conferences - Bluefield Daily Telegraph
Verastem, Inc. (NASDAQ:VSTM) Stock Holdings Lowered by XTX Topco Ltd - The AM Reporter
Verastem (VSTM) to Release Earnings on Thursday - Defense World
B. Riley Has Positive Forecast for Verastem FY2029 Earnings - Defense World
BlackRock, Inc. Expands Stake in Verastem Inc. with Recent Acqui - GuruFocus
Does Verastem Inc (VSTM) offer a good opportunity for investors? - Sete News
Verastem Inc (VSTM) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):